Free Trial

Omnicell (OMCL) Stock Price, News & Analysis

Omnicell logo
$29.56 -0.24 (-0.81%)
Closing price 07/3/2025 02:32 PM Eastern
Extended Trading
$29.56 +0.00 (+0.00%)
As of 07/3/2025 04:40 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Omnicell Stock (NASDAQ:OMCL)

Key Stats

Today's Range
$29.68
$30.28
50-Day Range
$24.63
$31.68
52-Week Range
$22.66
$55.75
Volume
185,031 shs
Average Volume
564,978 shs
Market Capitalization
$1.38 billion
P/E Ratio
64.26
Dividend Yield
N/A
Price Target
$44.83
Consensus Rating
Moderate Buy

Company Overview

Omnicell Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
56th Percentile Overall Score

OMCL MarketRank™: 

Omnicell scored higher than 56% of companies evaluated by MarketBeat, and ranked 486th out of 929 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Omnicell has received a consensus rating of Moderate Buy. The company's average rating score is 2.57, and is based on 4 buy ratings, 3 hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Omnicell has only been the subject of 4 research reports in the past 90 days.

  • Read more about Omnicell's stock forecast and price target.
  • Earnings Growth

    Earnings for Omnicell are expected to grow by 13.76% in the coming year, from $1.09 to $1.24 per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Omnicell is 64.26, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 25.65.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Omnicell is 64.26, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 27.66.

  • Price to Book Value per Share Ratio

    Omnicell has a P/B Ratio of 1.10. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Read more about Omnicell's valuation and earnings.
  • Percentage of Shares Shorted

    5.39% of the float of Omnicell has been sold short.
  • Short Interest Ratio / Days to Cover

    Omnicell has a short interest ratio ("days to cover") of 3.8, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Omnicell has recently increased by 8.37%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    Omnicell does not currently pay a dividend.

  • Dividend Growth

    Omnicell does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    5.39% of the float of Omnicell has been sold short.
  • Short Interest Ratio / Days to Cover

    Omnicell has a short interest ratio ("days to cover") of 3.8, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Omnicell has recently increased by 8.37%, indicating that investor sentiment is decreasing significantly.
  • News Sentiment

    Omnicell has a news sentiment score of 1.88. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.57 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 1 news article for Omnicell this week, compared to 6 articles on an average week.
  • Insider Buying vs. Insider Selling

    In the past three months, Omnicell insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    Only 2.52% of the stock of Omnicell is held by insiders.

  • Percentage Held by Institutions

    97.70% of the stock of Omnicell is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Omnicell's insider trading history.
Receive OMCL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Omnicell and its competitors with MarketBeat's FREE daily newsletter.

OMCL Stock News Headlines

A new rule goes live in July — and the banks are quietly cashing in
A little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Street and the Big Banks… It gives them the green light to treat a certain tangible asset as equivalent to cold, hard cash. Not stocks. Not real estate. And definitely not the U.S. dollar. We're talking about something they don't want you to notice — because the fewer people who act on this, the better it is for them.
3 Cash-Heavy Stocks Facing Headwinds
Omnicell CFO Nchacha Etta to Step Down
See More Headlines

OMCL Stock Analysis - Frequently Asked Questions

Omnicell's stock was trading at $44.52 at the start of the year. Since then, OMCL stock has decreased by 33.6% and is now trading at $29.5590.

Omnicell, Inc. (NASDAQ:OMCL) announced its earnings results on Tuesday, May, 6th. The company reported $0.26 earnings per share for the quarter, beating analysts' consensus estimates of $0.16 by $0.10. The firm's revenue for the quarter was up 9.5% compared to the same quarter last year.
Read the conference call transcript
.

Omnicell subsidiaries include MarkeTouch Media LLC, ReCept Pharmacy, FDS Amplicare, 340B Link Business, InPharmics, Ateb Inc., Aesynt, and others.

Shares of OMCL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Omnicell investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Tesla (TSLA), Netflix (NFLX), Broadcom (AVGO) and Palo Alto Networks (PANW).

Company Calendar

Last Earnings
5/06/2025
Today
7/05/2025
Next Earnings (Estimated)
7/30/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MEDICAL INFO SYS
Sub-Industry
Health Care Technology
Current Symbol
NASDAQ:OMCL
Employees
3,670
Year Founded
1992

Price Target and Rating

Average Stock Price Target
$44.83
High Stock Price Target
$64.00
Low Stock Price Target
$34.00
Potential Upside/Downside
+51.7%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.57
Research Coverage
7 Analysts

Profitability

Trailing P/E Ratio
64.26
Forward P/E Ratio
27.12
P/E Growth
N/A
Net Income
$12.53 million
Pretax Margin
2.98%

Debt

Sales & Book Value

Annual Sales
$1.11 billion
Cash Flow
$3.03 per share
Price / Cash Flow
9.75
Book Value
$26.84 per share
Price / Book
1.10

Miscellaneous

Free Float
45,664,000
Market Cap
$1.38 billion
Optionable
Optionable
Beta
0.76

Social Links

2025 Gold Forecast: A Perfect Storm for Demand Cover

Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.

Get This Free Report

This page (NASDAQ:OMCL) was last updated on 7/5/2025 by MarketBeat.com Staff
From Our Partners